HUTCHMED: AstraZeneca Submits US NDA for ORPATHYS + TAGRISSO in MET-Driven EGFR-Mutant Lung Cancer
HCM sits 46% above its 52-week low of $9.77.
Summary
AstraZeneca submitted a US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutant NSCLC, supported by positive Phase III SAFFRON data. This is the first US regulatory filing for the combination.
Key Events · Product Development and Regulatory · HCM
-
US NDA Submitted for ORPATHYS + TAGRISSO
AstraZeneca submitted a New Drug Application to the US FDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in locally advanced or metastatic NSCLC with MET overexpression or amplification after progression on EGFR-TKI therapy.
-
SAFFRON Phase III Supports Filing
The global SAFFRON trial showed statistically significant and clinically meaningful improvements in both progression-free survival and overall survival versus doublet platinum-based chemotherapy in 338 patients across 29 countries.
-
Large Addressable Patient Population
An estimated 34% of tumors develop high MET overexpression or amplification after progression on a third-generation EGFR TKI, representing a significant unmet need in EGFR-mutant NSCLC.
-
ESMO Presidential Symposium Presentation
Full SAFFRON results will be presented in a Presidential Symposium at the upcoming ESMO Congress 2026, providing additional visibility to the data.
Analysis · HCM · Life Sciences
AstraZeneca has filed a US New Drug Application for the ORPATHYS plus TAGRISSO combination in MET-driven EGFR-mutant NSCLC. This is the first US regulatory submission for this combination and follows positive Phase III SAFFRON data showing statistically significant improvements in both progression-free and overall survival. Approval would open a major US market opportunity for HUTCHMED's savolitinib, with an estimated 34% of tumors developing high MET overexpression or amplification after progression on a third-generation EGFR TKI. The filing also builds on prior China approval based on the SACHI trial and a Swiss temporary authorization based on SAVANNAH.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 40% of the 995 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $14.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $9.77 to $16.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.